3/31/2014 11:07:30 AM
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, announced today an agreement with Penn Pharma to manufacture Validive®, currently in a late phase II trial for the prevention and treatment of severe oral mucositis induced by radiotherapy and/or chemotherapy in head and neck cancer patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by